SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 27, 2013
Delaware 000-6658 04-2217279 _______________ _____________ __________________ (State or other (Commission (IRS Employer No.) jurisdiction of File Number) incorporation) |
ITEM 1.02. Termination of a Material Definitive Agreement
See Item 8.01 for termination of the Research and Development Agreement between BioDox R&D Corporation and the Company's subsidiary, Scientific Bioprocessing, Inc.
ITEM 8.01. Termination of a Material Definitive Agreement
In June 2013, Scientific Bioprocessing, Inc, a wholly-owned
subsidiary of the Company, terminated its Research and
Development Agreement with BioDox R&D Corporation
(the "Developer") formerly Fluorometrix Inc., pursuant to
Section 7.2(b)(iii) of the Agreement due to the death of
Dr. Joseph E. Qualitz, the Developer's Chief Operating Officer.
The R&D Agreement provides that the Agreement terminate
immediately upon the cessation of Qualitz "to carry out and be
responsible for the day-to-day business operation of Developer
unless the Company consents in writing to a replacement who has
similar skills, education, experience and capabilities." The
Company believes that the termination will not be materially
adverse to the Company's operation or financial condition as it
believes the research and development can be performed by its
staff, or if needed, through qualified subcontractors at no
additional material increase in cost from that to be incurred
if the agreement was not terminated.
ITEM 9.01 Financial Statements and Exhibits
(a) and (b) not applicable
(c) Exhibits
Exhibit No. Exhibit
___________ _____________________________
99.1 Research and Development Agreement between
Scientific Bioprocessing, Inc, and BioDox
R&D Corporation, dated November 14, 2011
(incorporated hereto by reference to Exhibit 10(B)
to Current Report on Form 8-K, dated November 14, 2011)
99.2 Notice of Termination of Reseearch and Development
Agreement
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SCIENTIFIC INDUSTRIES, INC.
(Registrant)
Date: June 27, 2013
By: /s/ Helena R. Santos
________________________
Helena R. Santos,
President and Chief Executive
Officer
|
Scientific Bioprocessing, Inc.
70 Orville Drive
Bohemia, New York 11716
June 12, 2013
BioDox R&D Corporation
24 Timber Edge Road
Stow, Massachusetts 01775
Gentlemen:
Please be advised that due to the death of Dr. Joseph E. Qualitz, Scientific Bioprocessing, Inc. (the "Company") has determined pursuant to Section 7.2(b)(iv) of the Research and Development Agreement dated November 14, 2011 between the Company and BioDox R&D Corporation (the "Developer"), to terminate the Agreement effective immediately.
Very truly yours,
SCIENTIFIC BIOPROCESSING, INC.
BY: /S/ HELENA R. SANTOS _____________________ Helena R. Santos, President |
cc: Mr. Thomas Alexander
c/o Fluorometrix Corporation
15913 S. Windy City Road
Mulino, OR 97042
Donna Qualitz
BioDox R&D Corporation
P.O. Box 816,
Stow MA 01775